One copied sentence can delay a regulatory launch. Here’s why approved wording can become a compliance risk in a new context.<\/p>\n
Approved wording feels safe. It passed legal review, quality review, and internal sign-off. Someone already said yes to it. So, when a deadline is tight and a new document needs drafting, pulling sentences from something that already worked is tempting and completely understandable.<\/p>\n
The problem is that “worked” only ever meant: worked in that document, for that audience, in that context. Move the text, and you move it without any of those conditions. That’s where a Request for Information starts: from a sentence copied from the wrong document.<\/p>\n
Not all regulatory documents do the same job, and they’re not read by the same people.<\/p>\n
An Informed Consent Form (ICF) is written for trial participants and held to standards of clarity and ethical adequacy. A Summary of Product Characteristics (SmPC) targets healthcare professionals who need precise clinical guidance. An Instructions for Use (IFU) goes to an end user who needs plain, unambiguous directions.<\/p>\n
When a risk description written for a clinical report migrates into a patient-facing IFU (word for word, because it was already approved), it doesn’t arrive in a vacuum. It arrives in the wrong context.<\/strong><\/p>\n What counts as adequate in one is not what counts as adequate in another, and wording that satisfies one instrument can be technically misleading in a different one.<\/p>\n Regulatory language is precise by nature, which means small changes in wording change what the text actually claims.<\/strong><\/p>\n The difference between the device shall not be used in patients with renal impairment<\/em> and the device should not be used in patients with renal impairment<\/em> is a single word. One is a prohibition. The other is a recommendation.<\/p>\n In a submission, that distinction can affect how the contraindication is interpreted and assessed. And if the weaker form ended up in the IFU because someone borrowed it from an earlier draft, a reviewer will catch it. The author may not have.<\/p>\n This is the kind of detail that generates a Request for Information and delays a launch.<\/p>\n Once wording enters a documentation set, it tends to stay. Teams reuse it because it’s been approved before. New documents inherit it. And if the original contained an error, or language that was accurate once but no longer reflects current guidance, that error travels.<\/p>\n By the time it surfaces, it may have propagated across multiple filings. At that time, the correction is no longer a quick edit.<\/strong><\/p>\n The numbers reflect this. The average cost of a compliance violation in pharma reached $14.8 million in 2024. That figure covers many types of failures, but documentation inconsistency is one of the most preventable.<\/p>\n A related problem appears when different teams work on different parts of a submission, and each pulls language from a different source document.<\/p>\n One document says device malfunction<\/em>. Another says technical failure<\/em>. \u201cSame concept,\u201d one may think, but now your dossier uses both, interchangeably, with no explanation.<\/p>\n During a regulatory review, documents aren’t read in isolation. They’re read together, against each other. Inconsistent terminology raises a straightforward question: Does this organization have control over its own documentation? <\/strong>That question is exactly what you don’t want a Notified Body or regulatory reviewer asking.<\/p>\n One common assumption worth challenging: if wording has been approved for one market, it can be reused for another.<\/p>\n The EU and the US are the clearest examples<\/strong>. The EU Medical Device Regulation (MDR) and the FDA share the same broad intent: safe, effective devices. However, they differ significantly in terminology, evidence requirements, and what needs to be documented, and how.<\/p>\n Beyond that, EU MDR requires that all user-facing documentation (i.e., labels, IFUs, any information that reaches the end user) be available in the official language of each Member State where the device is sold.<\/p>\n A submission built on “globally approved text” may raise questions a Notified Body shouldn\u2019t have to ask.<\/p>\n All of this becomes more complex in multilingual submissions, which, for most companies operating internationally, means all of their submissions.<\/p>\n When text has been copied across documents and then translated at different points in time, by different translators, without a shared terminology reference, you end up with multiple translations of the same original phrase. Different words and different regulatory implications across languages that are being reviewed simultaneously.<\/p>\n Which means the fix has to start in the same place the problem does: the source. Specifically, removing the conditions that make copy-paste risky in the first place. That means:<\/p>\nThe Details Reviewers Notice, Even When Authors Don\u2019t<\/h2>\n
How an Error Compounds Across a Dossier<\/h2>\n
Inconsistent Terminology Across Teams Reads as Loss of Control<\/h2>\n
“Globally Approved Text” Isn’t Really a Thing<\/h2>\n
When Translation Exposes What Governance Should Have Caught<\/h2>\n